A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, tolerability, and safety of 12-weeks
of treatment with TMC435 plus pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV)
in previously untreated adult participants with genotype 1 or genotype 4 chronic Hepatitis C
Virus (HCV) infection.